Pioneering a new generation of advanced pharmaceuticals
Adare Pharma Solutions, in collaboration with Laxxon Medical, offers clinical scale cGMP 3D screen printing capabilities from Adare facilities in the US and Europe. This innovative technology empowers a wide range of enhanced dose flexibility capabilities.
- Customized medicines
- Multi-drug medications
- Reduction of daily pills
- Tailored drug release
- Combine IR, ER, and DR
- Standard excipients
- 505(b)2 extension
- Longer IP protection
3D screen printing allows for the formulation of complex pharmaceuticals with optimized properties, including freely customizable release profiles of one or more APIs, improved bioavailability, shape modifications for ease of swallowing, and tailored pharmacokinetics.
The platform enables production of multi-compartment tablets ranging from as small as 200 microns up to centimeters in diameter, as well as a direct upscale from lab- to mass-production without changing the production process.
3D Screen Printing is offered from our Pessano facility in Milan, Italy. This flexible cGMP suite permits direct scaling from laboratory quantities through to clinical trial material volumes. Commercial scale equipment will be added at a later date.
To learn more about our 3D Screen Printing capabilities, contact us today to speak with our drug delivery experts.
Speak With An Expert
Nathan Dormer
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS and Philadelphia, PA facilities, where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.